Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0157)
Name
Beta-Elemene
Synonyms
BETA-ELEMENE; 515-13-9; (-)-beta-Elemene; beta-Elemen; Levo-beta-elemene; Elemene; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; b-elemene; beta-Elemene, (-)-; CHEBI:62855; Levo-b-elemene; UNII-2QG8CX6LXD; 2QG8CX6LXD; (-)-b-Elemene; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; 33880-83-0; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; ELEMENE, (-)-BETA-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; .beta.-Elemene; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-; EINECS 251-713-0; (-)-.beta.-Elemene; b-Elemen; (-)-bete-elemene; E- .beta.-Elemene; Beta elemene [WHO-DD]; Epitope ID:153551; (1S,2S,4R)-beta-elemene; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; CHEBI:62854; DTXSID40865690; DTXSID60881211; SDP-111; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1alpha,2beta,4beta)-; OPFTUNCRGUEPRZ-QLFBSQMISA-N; ELEMENE, (-)-.BETA.-; s6957; AKOS028108977; (-)-beta-Elemene, analytical standard; AS-82909; HY-107324; CS-0028143; C17094; E79113; EN300-1709739; Q27132237; rel-(1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; rel-(1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; (1alpha,2beta,4beta)-1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)cyclohexane

    Click to Show/Hide
Structure
Formula
C15H24
IUPAC Name
(1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane
Canonical SMILES
CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C
InChI
InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1
InChIKey
OPFTUNCRGUEPRZ-QLFBSQMISA-N
PubChem CID
6918391
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell adhesion molecules hsa04514
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
In Vitro Model HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
LoVo cells Colon adenocarcinoma Homo sapiens CVCL_0399
Caco-2 cells Colon adenocarcinoma Homo sapiens CVCL_0025
In Vivo Model
5-week-old female BALB/c nude were purchased from Shanghai Slac Laboratory Animal Co., Ltd. HCT116-luc cells were digested and washed by cold PBS for three times, and the final concentration was 2.5 x 106/ml in cold PBS. A volume of 100 ul cell suspension was injected subcutaneously into right dorsal flank of mice. When the tumor tissue in the subcutaneous was macroscopic, the tumor tissues were dissected and embedded into the mesentery of mice.

    Click to Show/Hide
Response regulation b-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant colorectal cancer cells.
References
Ref 1 Combinative treatment of -elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020 Apr 6;10(11):5107-5119. doi: 10.7150/thno.44705. eCollection 2020.